Per Stenkrona

Publications
CV
Public outreach and news

Articles

Article: JOURNAL OF NUCLEAR MEDICINE. 2022;63(12):1919-1924
First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B
Wakabayashi Y; Stenkrona P; Arakawa R; Yan X; Van Buskirk MG; Jenkins MD; Santamaria JAM; Maresca KP; Takano A; Liow J-S; Chappie TA; Varrone A; Nag S; Zhang L; Hughes ZA; Schmidt CJ; Doran SD; Mannes A; Zanotti-Fregonara P; Ooms M; Morse CL; Zoghbi SS; Halldin C; Pike VW; Innis RB
Article: NEURO-ONCOLOGY. 2021;23(4):687-696
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study
Jucaite A; Stenkrona P; Cselenyi Z; De Vita S; Buil-Bruna N; Varnas K; Savage A; Varrone A; Johnstrom P; Schou M; Davison C; Sykes A; Reddy VP; Hoch M; Vazquez-Romero A; Moein MM; Halldin C; Merchant MS; Pass M; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2020;47(10):2429-2439
PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [¹⁸F]PF-06684511
Arakawa R; Takano A; Stenkrona P; Stepanov V; Nag S; Jahan M; Gryback P; Bolin M; Chen L; Zhang L; He P; Villalobos A; McCarthy TJ; Halldin C; Varrone A
Article: EJNMMI RESEARCH. 2020;10(1):59
Quantification and reliability of [¹¹C]VC-002 binding to muscarinic acetylcholine receptors in the human lung - a test-retest PET study in control subjects
Cselenyi Z; Jucaite A; Kristensson C; Stenkrona P; Ewing P; Varrone A; Johnstrom P; Schou M; Vazquez-Romero A; Moein MM; Bolin M; Siikanen J; Gryback P; Larsson B; Halldin C; Grime K; Eriksson UG; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2019;46(11):2329-2338
Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [¹¹C]PBR28 HRRT PET study
Tuisku J; Plaven-Sigray P; Gaiser EC; Airas L; Al-Abdulrasul H; Bruck A; Carson RE; Chen M-K; Cosgrove KP; Ekblad L; Esterlis I; Farde L; Forsberg A; Halldin C; Helin S; Kosek E; Lekander M; Lindgren N; Marjamaki P; Rissanen E; Sucksdorff M; Varrone A; Collste K; Gallezot J-D; Hillmer A; Huang Y; Hoglund CO; Johansson J; Jucaite A; Lampa J; Nabulsi N; Pittman B; Sandiego CM; Stenkrona P; Rinne J; Matuskey D; Cervenka S
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2019;22(7):415-425
D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
Stenkrona P; Matheson GJ; Halldin C; Cervenka S; Farde L
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2019;22(4):278-285
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [¹⁸F]FMeNER-D₂
Arakawa R; Stenkrona P; Takano A; Svensson J; Andersson M; Nag S; Asami Y; Hirano Y; Halldin C; Lundberg J
Article: NEUROIMAGE. 2019;188:102-110
Accuracy and reliability of [¹¹C]PBR28 specific binding estimated without the use of a reference region
Plaven-Sigray P; Schain M; Zanderigo F; Farde L; Halldin C; Forsberg A; Varrone A; Jucaite A; Cervenka S; Stenkrona P; Collste K; Kander M; Kosek E; Lampa J; Hoglund CO; Rabiner EA; Gunn RN; Ogden RT; Cervenk S
Article: EJNMMI RESEARCH. 2018;8(1):74
[¹¹C]SCH23390 binding to the D₁-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis
Stenkrona P; Matheson GJ; Cervenka S; Sigray PP; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2018;45(9):1605-1617
Dual tracer tau PET imaging reveals different molecular targets for ¹¹C-THK5351 and ¹¹C-PBB3 in the Alzheimer brain
Chiotis K; Stenkrona P; Almkvist O; Stepanov V; Ferreira D; Arakawa R; Takano A; Westman E; Varrone A; Okamura N; Shimada H; Higuchi M; Halldin C; Nordberg A
Article: PLOS ONE. 2018;13(3):e0193770
Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study
Plaven-Sigray P; Matheson GJ; Gustavsson P; Stenkrona P; Halldin C; Farde L; Cervenka S
Article: EJNMMI RESEARCH. 2017;7(1):54
Test-retest reproducibility of [¹¹C]-Ldeprenyl-D2 binding to MAO-B in the human brain
Arakawa R; Stenkrona P; Takano A; Nag S; Maior RS; Halldin C
Article: NEUROIMAGE. 2017;155:344-353
Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [¹¹C] SCH-23390
Matheson GJ; Stenkrona P; Cselenyi Z; Plaven-Sigray P; Halldin C; Farde L; Cervenka S
Article: NEUROPHARMACOLOGY. 2017;117:171-181
In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects
Delnomdedieu M; Forsberg A; Ogden A; Fazio P; Yu C-R; Stenkrona P; Duvvuri S; David W; Al-Tawil N; Vitolo OV; Amini N; Nag S; Halldin C; Varrone A
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2017;44(3):382-391
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline
Sturm S; Forsberg A; Nave S; Stenkrona P; Seneca N; Varrone A; Comley RA; Fazio P; Jamois C; Nakao R; Ejduk Z; Al-Tawil N; Akenine U; Halldin C; Andreasen N; Ricci B
Article: PSYCHOPHARMACOLOGY. 2017;234(4):707-716
GABA_A receptor occupancy by subtype selective GABA_Aα2,3 modulators: PET studies in humans
Jucaite A; Cselenyi Z; Lappalainen J; McCarthy DJ; Lee C-M; Nyberg S; Varnas K; Stenkrona P; Halldin C; Cross A; Farde L
Article: NEUROIMAGE. 2016;141:10-17
A human [¹¹C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor
Takano A; Stenkrona P; Stepanov V; Amini N; Martinsson S; Tsai M; Goldsmith P; Xie J; Wu J; Uz T; Halldin C; Macek TA
Article: MOLECULAR PSYCHIATRY. 2016;21(8):1077-1084
Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain
Borg J; Cervenka S; Kuja-Halkola R; Matheson GJ; Jonsson EG; Lichtenstein P; Henningsson S; Ichimiya T; Larsson H; Stenkrona P; Halldin C; Farde L
Article: NEUROIMAGE. 2014;102:590-595
Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study
Plaven-Sigray P; Gustavsson P; Farde L; Borg J; Stenkrona P; Nyberg L; Backman L; Cervenka S
Article: NEUROIMAGE. 2013;82:160-169
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-Estimating occupancy in the absence of a reference region
Kadgedal M; Cselenyi Z; Nyberg S; Raboisson P; Stahle L; Stenkrona P; Varnas K; Halldin C; Hooker AC; Karlsson MO
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2013;23(10):1190-1198
5-HTT and 5-HT_1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects
Stenkrona P; Halldin C; Lundberg J
Article: CEPHALALGIA. 2013;33(10):853-860
A PET study with [¹¹C]AZ10419369 to determine brain 5-HT_1B receptor occupancy of zolmitriptan in healthy male volunteers
Varnas K; Jucaite A; McCarthy DJ; Stenkrona P; Nord M; Halldin C; Farde L; Kanes S
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2013;16(6):1231-1239
AZD5213: a novel histamine H₃ receptor antagonist permitting high daytime and low nocturnal H₃ receptor occupancy, a PET study in human subjects
Jucaite A; Takano A; Bostrom E; Jostell K-G; Stenkrona P; Halldin C; Segerdahl M; Nyberg S
Article: EJNMMI RESEARCH. 2013;3(1):30
In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [¹⁸F]FEDAA1106
Takano A; Piehl F; Hillert J; Varrone A; Nag S; Gulyas B; Stenkrona P; Villemagne VL; Rowe CC; Macdonell R; Al Tawil N; Kucinski T; Zimmermann T; Schultze-Mosgau M; Thiele A; Hoffmann A; Halldin C
Article: NEUROIMAGE. 2012;61(4):849-856
Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers
Kagedal M; Cselenyi Z; Nyberg S; Jonsson S; Raboisson P; Stenkrona P; Hooker AC; Karlsson MO
Article: EJNMMI RESEARCH. 2012;2:15
Kinetic analysis and test-retest variability of the radioligand [¹¹C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects
Jucaite A; Cselenyi Z; Arvidsson A; Ahlberg G; Julin P; Varnas K; Stenkrona P; Andersson J; Halldin C; Farde L
Article: NEUROIMAGE. 2012;60(1):800-807
Quantification of serotonin transporter availability with [¹¹C]MADAM - A comparison between the ECAT HRRT and HR systems
Schain M; Toth M; Cselenyi Z; Stenkrona P; Halldin C; Farde L; Varrone A
Article: NEUROIMAGE. 2012;59(4):3582-3593
Quantitative PET analyses of regional [¹¹C]PE2I binding to the dopamine transporter - Application to juvenile myoclonic epilepsy
Odano I; Varrone A; Savic I; Ciumas C; Karlsson P; Jucaite A; Halldin C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2011;38(11):2058-2065
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [¹⁸F]FEDAA1106: a human whole-body PET study
Takano A; Gulyas B; Varrone A; Karlsson P; Sjoholm N; Larsson S; Jonsson C; Odh R; Sparks R; Al Tawil N; Hoffmann A; Zimmermann T; Thiele A; Halldin C
Article: HUMAN BRAIN MAPPING. 2011;32(10):1626-1636
Extrastriatal Dopamine D₂ Receptor Binding in Huntington's Disease
Esmaeilzadeh M; Farde L; Karlsson P; Varrone A; Halldin C; Waters S; Tedroff J
Article: NEUROBIOLOGY OF AGING. 2011;32(10):1849-1856
Dopamine D₁ receptors and age differences in brain activation during working memory
Backman L; Karlsson S; Fischer H; Karlsson P; Brehmer Y; Rieckmann A; MacDonald SWS; Farde L; Nyberg L
Article: CEREBRAL CORTEX. 2011;21(9):2023-2032
Dopamine D1 Receptor Associations within and between Dopaminergic Pathways in Younger and Elderly Adults: Links to Cognitive Performance
Rieckmann A; Karlsson S; Karlsson P; Brehmer Y; Fischer H; Farde L; Nyberg L; Backman L
Article: NEUROIMAGE. 2011;57(2):346-351
Relationship of dopamine D1 receptor binding in striatal and extrastriatal regions to cognitive functioning in healthy humans
Karlsson S; Rieckmann A; Karlsson P; Farde L; Nyberg L; Backman L
Article: PSYCHOPHARMACOLOGY. 2011;213(2-3):533-545
Dose-dependent binding of AZD3783 to brain 5-HT_1B receptors in non-human primates and human subjects: a positron emission tomography study with [¹¹C]AZ10419369
Varnas K; Nyberg S; Karlsson P; Pierson ME; Kagedal M; Cselenyi Z; McCarthy D; Xiao A; Zhang M; Halldin C; Farde L
Article: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2011;31(1):113-123
Quantitative analysis of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in human brain
Varnas K; Nyberg S; Halldin C; Varrone A; Takano A; Karlsson P; Andersson J; McCarthy D; Smith M; Pierson ME; Soderstrom J; Farde L
Article: NEUROSCIENCE. 2010;167(1):104-110
AGE-RELATED REDUCTION IN DOPAMINE D1 RECEPTORS IN THE HUMAN BRAIN: FROM LATE CHILDHOOD TO ADULTHOOD, A POSITRON EMISSION TOMOGRAPHY STUDY
Jucaite A; Forssberg H; Karlsson P; Halldin C; Farde L
Article: BIOLOGICAL PSYCHIATRY. 2010;67(6):575-580
Simulating Neurocognitive Aging: Effects of a Dopaminergic Antagonist on Brain Activity During Working Memory
Fischer H; Nyberg L; Karlsson S; Karlsson P; Brehmer Y; Rieckmann A; MacDonald SWS; Farde L; Backman L
Article: NEUROIMAGE. 2009;48(2):398-404
Modulation of striatal dopamine D1 binding by cognitive processing
Karlsson S; Nyberg L; Karlsson P; Fischer H; Thilers P; MacDonald S; Brehmer Y; Rieckmann A; Halldin C; Farde L; Backman L
Article: PSYCHIATRY RESEARCH. 2009;172(1):31-37
5-HT_1A receptor and 5-HTT binding during the menstrual cycle in healthy women examined with [¹¹C] WAY100635 and [¹¹C] MADAM PET
Jovanovic H; Karlsson P; Cerin A; Halldin C; Nordstrom A-L
Article: NEUROIMAGE. 2009;45(3):891-902
[¹⁸F]Flumazenil binding to central benzodiazepine receptor studies by PET - Quantitative analysis and comparisons with [¹¹C]flumazenil
Odano I; Halldin C; Karlsson P; Varrone A; Airaksinen AJ; Krasikova RN; Farde L
Article: NEUROIMAGE. 2008;42(2):474-482
Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[¹⁸F]FMeNER-D₂
Takano A; Varrone A; Gulyas B; Karlsson P; Tauscher J; Halldin C
Article: NEUROIMAGE. 2008;41(3):1075-1085
[¹¹C]AZ10419369:: A selective 5-HT_1B receptor radioligand suitable for positron emission tomography (PET).: Characterization in the primate brain
Pierson ME; Andersson J; Nyberg S; McCarthy DJ; Finnema SJ; Varnas K; Takano A; Karlsson P; Gulyas B; Medd AM; Lee C-M; Powell ME; Heys JR; Potts W; Seneca N; Mrzljak L; Farde L; Halldin C
Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2008;11(2):163-171
PET analysis of the 5-HT_2A receptor inverse agonist ACP-103 in human brain
Nordstrom A-L; Mansson M; Jovanovic H; Karlsson P; Halldin C; Farde L; Vanover KE; Hacksell U; Brann MR; Davis RE; Weiner DM
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2008;35(3):630-636
Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[¹⁸F]FMeNER-D₂:: a human whole-body PET study
Takano A; Halldin C; Varrone A; Karlsson P; Sjoeholm N; Stubbs JB; Schou M; Airaksinen AJ; Tauscher J; Gulyas B
Article: NEUROIMAGE. 2008;39(3):1408-1419
Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET
Jovanovic H; Lundberg J; Karlsson P; Cerin A; Saijo T; Varrone A; Halldin C; Nordstrom A-L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2008;35(1):153-157
Imaging the norepinephrine transporter with positron emission tomography:: initial human studies with (S,S)-[¹⁸F]FMeNER-D₂
Takano A; Gulyas B; Varrone A; Karlsson P; Schou M; Airaksinen AJ; Vandenhende F; Tauscher J; Halldin C
Article: PSYCHIATRY RESEARCH. 2006;148(2-3):185-193
A PET study of 5-HT_1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria
Jovanovic H; Cerin A; Karlsson P; Lundberg J; Halldin C; Nordstrom A-L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2003;30(11):1520-1528
Radioiodinated SB 207710 as a radioligand in vivo:: imaging of brain 5-HT₄ receptors with SPET
Pike VW; Halldin C; Nobuhara K; Hiltunen J; Mulligan RS; Swahn CG; Karlsson P; Olsson H; Hume SP; Hirani E; Whalley J; Pilowsky LS; Larsson S; Schnell PO; Ell PJ; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2003;30(9):1220-1230
[¹¹C]PE2I:: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain
Halldin C; Erixon-Lindroth N; Pauli S; Chou YH; Okubo Y; Karlsson P; Lundkvist C; Olsson H; Guilloteau D; Emond P; Farde L
Article: ACTA NEUROLOGICA SCANDINAVICA. 2002;106(6):325-332
PET studies on the brain uptake and regional distribution of [¹¹C] vinpocetine in human subjects
Gulyás B; Halldin C; Sandell J; Karlsson P; Sóvágó J; Kárpáti E; Kiss B; Vas A; Cselényi Z; Farde L
Article: ORVOSI HETILAP. 2002;143(47):2631-2636
[Cerebral uptake and regional distribution of [11C]-vinpocetin after intravenous administration to healthy men: a PET study].
Vas A; Sóvágó J; Halldin C; Sandell J; Karlsson P; Kárpáti E; Kiss B; Cselényi Z; Farde L; Gulyás B
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2001;28(1):13-24
SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP
Nobuhara K; Farde L; Halldin C; Karlsson P; Swahn CG; Olsson H; Bergström KA; Larsson SA; Schnell PO; McPherson DW; Savonen A; Hiltunen J; Sedvall G
Article: PSYCHOPHARMACOLOGY. 2000;149(1):45-55
Z-IQNP:: a potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer's disease
Nobuhara K; Halldin C; Hall H; Karlsson P; Farde L; Hiltunen J; McPherson DW; Savonen A; Bergström KA; Pauli S; Swahn CG; Larsson SA; Schnell PO; Sedvall G
Article: NEUROPSYCHOPHARMACOLOGY. 1999;21(6):S181-S188
Pharmacological manipulation of D₁-dopamine receptor function in schizophrenia
Sedvall GC; Karlsson P
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1999;26(11):1482-1485
Iodine-123 labelled Z-(R,R)-IQNP:: a potential radioligand for visualization of M₁ and M₂ muscarinic acetylcholine receptors in Alzheimer's disease
Bergström KA; Halldin C; Savonen A; Okubo Y; Hiltunen J; Nobuhara K; Swahn CG; Karlsson P; McPherson D; Knapp FF; Larsson S; Schnell PO; Farde L
Article: JOURNAL OF NEUROIMAGING. 1999;9(4):217-222
Brain uptake and plasma metabolism of [¹¹C]vinpocetine:: A preliminary PET study in a cynomolgus monkey
Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöck P; Paróczai M; Farde L
Article: PSYCHOPHARMACOLOGY. 1999;146(2):220-227
A PET study of D₁-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain
Chou YH; Karlsson P; Halldin C; Olsson H; Farde L
Article: ORVOSI HETILAP. 1999;140(30):1687-1691
[Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies].
Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöczk P; Farde L
Article: JOURNAL OF NUCLEAR MEDICINE. 1998;39(12):2061-2068
Carbon-11-NNC 112:: A radioligand for PET examination of striatal and neocortical D₁-dopamine receptors
Halldin C; Foged C; Chou YH; Karlsson P; Swahn CG; Sandell J; Sedvall G; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1998;25(5):503-508
[¹¹C]NNC 22-0215, a metabolically stable dopamine D₁ radioligand for PET
Foged C; Halldin C; Swahn CG; Ginovart N; Karlsson P; Lundkvist C; Farde L
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1998;25(4):338-346
[carbonyl-¹¹C]desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT_1A receptors in vitro and in vivo
Pike VW; Halldin C; McCarron JA; Lundkvist C; Hirani E; Olsson H; Hume SP; Karlsson P; Osman S; Swahn CG; Hall H; Wikström H; Mensonidas M; Poole KG; Farde L
Article: PSYCHOPHARMACOLOGY. 1997;133(4):396-404
A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients
Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 1997;24(10):1261-1267
Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET)
Foged C; Halldin C; Loch C; Maziere B; Pauli S; Maziere M; Hansen HC; Suhara T; Swahn CG; Karlsson P; Farde L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(6):837-844
C-11- and Br-76-labelled NNC 22-0010, selective dopamine D-1 receptor radioligands for PET
Foged C; Halldin C; Loch C; Maziere B; Karlsson P; Maziere M; Swahn CG; Farde L
Article: DEMENTIA. 1996;7(4):187-195
PET study of the M(1)-agonists [C-11]xanomeline and [C-11]butylthio-TZTP in monkey and man
Farde L; Suhara T; Halldin C; Nyback H; Nakashima Y; Swahn CG; Karlsson P; Ginovart N; Bymaster FP; Shannon HE; Foged C; Suzdak PD; Sauerberg P
Article: SYNAPSE. 1996;22(4):386-390
[C-11] beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography
Halldin C; Farde L; Lundkvist C; Ginovart N; Nakashima Y; Karlsson P; Swahn CG
Article: NUCLEAR MEDICINE AND BIOLOGY. 1996;23(3):201-209
Development of I-123-labelled NNC 13-8241 as a radioligand for SPECT visualization of benzodiazepine receptor binding
Foged C; Halldin C; Hiltunen J; Braestrup C; Thomsen C; Hansen HC; Suhara T; Pauli S; Swahn CG; Karlsson P; Larsson S; Farde L
Article: ANNALS OF NUCLEAR MEDICINE. 1996;10(1):85-88
Effects of cocaine on [11C]norepinephrine and [11C] beta-CIT uptake in the primate peripheral organs measured by PET.
Suhara T; Farde L; Halldin C; Någren K; Karlsson P
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(8):1053-1056
PET EXAMINATION OF THE MONKEY HEART WITH HIGH SPECIFIC RADIOACTIVITY [C-11] NOREPINEPHRINE AND [C-11] METARAMINOL
FARDE L; HALLDIN C; NAGREN K; KARLSSON P; SWAHN CG; SUHARA T
Article: AMERICAN JOURNAL OF PSYCHIATRY. 1995;152(10):1444-1449
D-1, D-2, AND 5-HT2 RECEPTOR OCCUPANCY IN RELATION TO CLOZAPINE SERUM CONCENTRATION - A PET STUDY OF SCHIZOPHRENIC-PATIENTS
NORDSTROM AL; FARDE L; NYBERG S; KARLSSON P; HALLDIN C; SEDVALL G
Article: PSYCHOPHARMACOLOGY. 1995;121(3):309-316
LACK OF APPARENT ANTIPSYCHOTIC EFFECT OF THE D-1-DOPAMINE RECEPTOR ANTAGONIST SCH39166 IN ACUTELY ILL SCHIZOPHRENIC-PATIENTS
KARLSSON P; SMITH L; FARDE L; HARNRYD C; SEDVALL G; WIESEL FA
Article: PSYCHOPHARMACOLOGY. 1995;121(3):300-308
EVALUATION OF SCH-39166 AS PET LIGAND FOR CENTRAL D-1 DOPAMINE-RECEPTOR BINDING AND OCCUPANCY IN MAN
KARLSSON P; SEDVALL G; HALLDIN C; SWAHN CG; FARDE L
Article: NUCLEAR MEDICINE AND BIOLOGY. 1995;22(7):905-913
[O-METHYL-C-11]BETA-CIT-FP, A POTENTIAL RADIOLIGAND FOR QUANTITATION OF THE DOPAMINE TRANSPORTER - PREPARATION, AUTORADIOGRAPHY, METABOLITE STUDIES, AND POSITRON EMISSION TOMOGRAPHY EXAMINATIONS
LUNDKVIST C; HALLDIN C; SWAHN CG; HALL H; KARLSSON P; NAKASHIMA Y; WANG SY; MILIUS RA; NEUMEYER JL; FARDE L
Article: NEUROSCIENCE. 1995;67(1):37-48
DISTRIBUTION OF MESSENGER-RNAS FOR D-1 DOPAMINE-RECEPTORS AND DARPP-32 IN STRIATUM AND CEREBRAL-CORTEX OF THE CYNOMOLGUS MONKEY - RELATIONSHIP TO D-1 DOPAMINE-RECEPTORS
BRENE S; HALL H; LINDEFORS N; KARLSSON P; HALLDIN C; SEDVALL G
Article: JOURNAL OF NUCLEAR MEDICINE. 1995;36(7):1275-1281
CARBON-11-FLB-457 - A RADIOLIGAND FOR EXTRASTRIATAL D2 DOPAMINE-RECEPTORS
HALLDIN C; FARDE L; HOGBERG T; MOHELL N; HALL H; SUHARA T; KARLSSON P; NAKASHIMA Y; SWAHN CG
Article: PSYCHOPHARMACOLOGY. 1995;119(1):1-8
ORAL-ADMINISTRATION OF NNC-756 - A PLACEBO-CONTROLLED PET STUDY OF D-1-DOPAMINE RECEPTOR OCCUPANCY AND PHARMACODYNAMICS IN MAN
KARLSSON P; FARDE L; HALLDIN C; SEDVALL G; YNDDAL L; SLOTHNIELSEN M
Article: ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES. 1995;32(1):22-29
RECENT DEVELOPMENTS IN PET SCAN IMAGING OF NEURORECEPTORS IN SCHIZOPHRENIA
SEDVALL G; PAULI S; FARDE L; KARLSSON P; NYBERG S; NORDSTROM AL
Article: CLINICAL NEUROSCIENCE. 1995;3(2):112-121
UTILIZATION OF RADIOLIGANDS IN SCHIZOPHRENIA RESEARCH
SEDVALL G; FARDE L; HALL H; HALLDIN C; KARLSSON P; NORDSTROM AL; NYBERG S; PAULI S
Show more

All other publications

Thesis / dissertation: 2021
Positron emission tomography studies of the D1-dopamine receptor in schizophrenia
Stenkrona, Per
Meeting abstract: NEUROIMAGE. 2010;52:S164-S165
Quantification of serotonin transporter availability with [11C]MADAM - A comparison between the ECAT HRRT and HR systems
Nilsson MS; Toth M; Cseleny Z; Karlsson P; Halldin C; Farde L; Varrone A
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2008;18:S82-S83
Lower 5-HT1A receptor binding in patients with borderline personality disorder:: a PET study using [¹¹C]WAY100635
Jovanovic H; Andersson EE; Karlsson P; Halldin C; Nordstroem AL; Asberg M; Farde L
Meeting abstract: NEUROIMAGE. 2008;41:T104
Quantitative analyses of [¹¹C]AZ10419369 binding to 5-HT_1B receptors in the human brain
Varnaes K; Nyberg S; Halldin C; Varrone A; Takano A; Karlsson P; McCarthy D; Smith M; Pierson ME; Soederstroem J; Farde L
Meeting abstract: NEUROIMAGE. 2008;41:T103
Mapping of the norepinephrine transporter in man using PET with (S,S)-[¹⁸F]FMeNER-D₂
Takano A; Varrone A; Gulyas B; Karlsson P; Tauscher J; Halldin C
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S289-S290
No changes in 5-HT1A receptor and serotonin transporter between phases of the menstrual cycle in healthy women
Jovanovic H; Karlsson P; Cerin A; Halldin C; Nordstrom AL
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S186
Gender differences in the 5-HT1A receptor and serotonin transporter in the human brain: a PET study
Jovanovic H; Lundberg J; Karlsson P; Cerin A; Halldin C; Nordstrom AL
Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S82-S83
Gender differences in the 5-HT1A receptor and serotonin transporter in the human brain: a PET study
Jovanovic H; Lundberg J; Cerin A; Karlsson P; Halldin C; Nordstrom AL
Meeting abstract: CLINICAL PHARMACOLOGY AND THERAPEUTICS. 2006;79(2):P74
Pharmacokinetics and dopamine D₂ and serotonin 5-HT_2A receptor occupancy of paliperidone in healthy subjects:: Two open-label, single-dose studies.
Karlsson P; Dencker E; Nyberg S; Mannaert E; Boom S; Talluri K; Rossenu S; Eriksson B; Eerdekens M; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T87
Dopamine transporter binding corrected for tissue heterogeneity and partial volume effect using [11C]PE2I and PET
Odano I; Jucaite A; Olsson H; Karlsson P; Pauli S; Halldin C; Farde L
Meeting abstract: NEUROIMAGE. 2006;31:T88
Comparisons of central benzodiazepine receptor mapping tracers, [18F]Flumazenil and [11C]Flumazenil presentation
Odano I; Farde L; Savic I; Ciumas C; Krasikova R; Airaksinen A; Karlsson P; Pauli S; Halldin C
Published conference paper: AMERICAN JOURNAL OF PSYCHIATRY. 2002;159(5):761-767
PET study of D₁ dopamine receptor binding in neuroleptic-naive patients with schizophrenia
Karlsson P; Farde L; Halldin C; Sedvall G
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1997;24(1-2):178-179
D-1-dopamine receptors in schizophrenia examined by PET
Karlsson P; Farde L; Halldin C; Sedvall G
Letter: AMERICAN JOURNAL OF PSYCHIATRY. 1996;153(9):1240
Unique receptor-blockading profile of clozapine - Reply
Nordstrom AL; Farde L; Nyberg S; Karlsson P; Halldin C; Sedvall G
Published conference paper: JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY. 1996;206(1):133-144
Development of radioligands for the dopamine transporter
Muller L; Halldin C; Lundkvist C; Swahn CG; Foged C; Hall H; Karlsson P; Ginovart N; Nakashima Y; Suhara T; Farde L
Meeting abstract: SCHIZOPHRENIA RESEARCH. 1995;15(1-2):86
DECREASED D-1-DOPAMINE RECEPTOR-BINDING IN DRUG-NAIVE SCHIZOPHRENIC-PATIENTS EXAMINED BY PET
KARLSSON P; FARDE L; HALLDIN C; SEDVALL G
Published conference paper: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1995;5:25-30
PET imaging of neuroreceptors in schizophrenia
Sedvall G; Pauli S; Karlsson P; Farde L; Nordstrom AL; Nyberg S; Halldin C
Published conference paper: CLINICAL NEUROPHARMACOLOGY. 1995;18:S121-S129
POSITRON EMISSION TOMOGRAPHY STUDIES ON DOPAMINE-RECEPTORS IN SCHIZOPHRENIA
FARDE L; NORDSTROM AL; KARLSSON P; HALLDIN C; SEDVALL G

Employments

Research Specialist, Department of Clinical Neuroscience, Karolinska Institutet, 2021-

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Clinical Neuroscience, Karolinska Institutet, 2021

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI